KRAS and metastatic colorectal cancer: Similarly, the anti-EGFR antibody cetuximab was associated with significant worsening of outcome when added to standard therapy in the treatment of KRAS-mutant metastatic colorectal cancer [35], while it may improve outcome in KRAS-wild-type patients [36].